D
Dejan Juric
Researcher at Harvard University
Publications - 272
Citations - 11263
Dejan Juric is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 41, co-authored 198 publications receiving 7200 citations. Previous affiliations of Dejan Juric include Stanford University & Massachusetts Eye and Ear Infirmary.
Papers
More filters
Journal ArticleDOI
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice Andre,Eva Ciruelos,G. Rubovszky,Mario Campone,Sibylle Loibl,Hope S. Rugo,H. Iwata,Pierfranco Conte,Ingrid A. Mayer,Bella Kaufman,Toshinari Yamashita,Yen-Shen Lu,Kenichi Inoue,Masato Takahashi,Zsuzsanna Papai,Anne-Sophie Longin,David Mills,Celine Wilke,Samit Hirawat,Dejan Juric +19 more
TL;DR: Treatment with alpelisib–fulvestrant prolonged progression‐free survival among patients with PIK3CA‐mutated, HR‐positive, HER2‐negative advanced breast cancer who had received endocrine therapy previously.
Journal ArticleDOI
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M. Hyman,Sarina Anne Piha-Paul,Helen Won,Jordi Rodon,Cristina Saura,Geoffrey I. Shapiro,Dejan Juric,David I. Quinn,Victor Moreno,Bernard Doger,Ingrid A. Mayer,Valentina Boni,Emiliano Calvo,Sherene Loi,Albert C. Lockhart,Joseph P. Erinjeri,Maurizio Scaltriti,Gary A. Ulaner,Juber Patel,Jiabin Tang,Hannah Beer,S. Duygu Selcuklu,Aphrothiti J. Hanrahan,Nancy Bouvier,Myra Melcer,Rajmohan Murali,Alison M. Schram,Lillian M. Smyth,Komal Jhaveri,Bob T. Li,Alexander Drilon,James J. Harding,Gopa Iyer,Barry S. Taylor,Michael F. Berger,Richard E. Cutler,Feng Xu,Anna Butturini,Lisa D. Eli,Grace Mann,Cynthia Farrell,Alshad S. Lalani,Richard Bryce,Carlos L. Arteaga,Funda Meric-Bernstam,José Baselga,David B. Solit +46 more
TL;DR: This study demonstrates how a molecularly driven clinical trial can be used to refine the biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.
Journal ArticleDOI
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric,Pau Castel,Malachi Griffith,Obi L. Griffith,Helen Won,Haley Ellis,Saya H. Ebbesen,Benjamin J. Ainscough,Avinash Ramu,Gopa Iyer,Ronak Shah,Tiffany Huynh,Mari Mino-Kenudson,Dennis C. Sgroi,Steven J. Isakoff,Ashraf Thabet,Leila Elamine,David B. Solit,Scott W. Lowe,Cornelia Quadt,Malte Peters,Adnan Derti,Robert Schegel,Alan Huang,Elaine R. Mardis,Michael F. Berger,José Baselga,Maurizio Scaltriti +27 more
TL;DR: Tumour genomic evolution in a patient with metastatic breast cancer bearing an activating PIK3CA mutation is studied, concluding that parallel genetic evolution of separate metastatic sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition.
Journal ArticleDOI
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets.
Toni Delorey,Carly G. K. Ziegler,Graham Heimberg,Rachelly Normand,Yiming Yang,Yiming Yang,Asa Segerstolpe,Domenic Abbondanza,Stephen J. Fleming,Ayshwarya Subramanian,Daniel T. Montoro,Karthik A. Jagadeesh,Kushal K. Dey,Pritha Sen,Michal Slyper,Yered Pita-Juárez,Devan Phillips,Jana Biermann,Zohar Bloom-Ackermann,Nikolaos Barkas,Andrea Ganna,Andrea Ganna,James Gomez,Johannes C. Melms,Igor Katsyv,Erica Normandin,Erica Normandin,Pourya Naderi,Pourya Naderi,Yury Popov,Yury Popov,Siddharth S. Raju,Siddharth S. Raju,Sebastian Niezen,Sebastian Niezen,Linus T.-Y. Tsai,Katherine J. Siddle,Katherine J. Siddle,Malika Sud,Victoria M. Tran,Shamsudheen K. Vellarikkal,Shamsudheen K. Vellarikkal,Yiping Wang,Liat Amir-Zilberstein,Deepak Atri,Deepak Atri,Joseph M. Beechem,Olga R. Brook,Jonathan H. Chen,Jonathan H. Chen,Prajan Divakar,Phylicia Dorceus,Jesse M. Engreitz,Jesse M. Engreitz,Adam Essene,Donna M. Fitzgerald,Robin Fropf,Steven Gazal,Joshua Gould,John Grzyb,Tyler Harvey,Jonathan L. Hecht,Jonathan L. Hecht,Tyler Hether,Judit Jané-Valbuena,Michael Leney-Greene,Hui Ma,Hui Ma,Cristin McCabe,Daniel E. McLoughlin,Eric M. Miller,Christoph Muus,Christoph Muus,Mari Niemi,Robert F. Padera,Robert F. Padera,Robert F. Padera,Liuliu Pan,Deepti Pant,Carmel Pe’er,Jenna Pfiffner-Borges,Christopher J. Pinto,Jacob Plaisted,Jason Reeves,Marty Ross,Melissa Rudy,Erroll H. Rueckert,Michelle Siciliano,Alexander Sturm,Ellen Todres,Avinash Waghray,Sarah Warren,Shuting Zhang,Daniel R. Zollinger,Lisa A. Cosimi,Rajat M. Gupta,Rajat M. Gupta,Nir Hacohen,Nir Hacohen,Hanina Hibshoosh,Winston Hide,Alkes L. Price,Jayaraj Rajagopal,Purushothama Rao Tata,Stefan Riedel,Stefan Riedel,Gyongyi Szabo,Gyongyi Szabo,Gyongyi Szabo,Timothy L. Tickle,Patrick T. Ellinor,Deborah T. Hung,Deborah T. Hung,Pardis C. Sabeti,Richard M. Novak,Robert S. Rogers,Robert S. Rogers,Donald E. Ingber,Donald E. Ingber,Donald E. Ingber,Z. Gordon Jiang,Z. Gordon Jiang,Dejan Juric,Mehrtash Babadi,Samouil L. Farhi,Benjamin Izar,James R. Stone,Ioannis S. Vlachos,Isaac H. Solomon,Orr Ashenberg,Caroline B. M. Porter,Bo Li,Bo Li,Alex K. Shalek,Alexandra-Chloé Villani,Orit Rozenblatt-Rosen,Orit Rozenblatt-Rosen,Aviv Regev +137 more
TL;DR: In this article, single-cell analysis of lung, heart, kidney and liver autopsy samples shows the molecular and cellular changes and immune response resulting from severe SARS-CoV-2 infection.
Journal ArticleDOI
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
Sadhna Vora,Dejan Juric,Nayoon Kim,Mari Mino-Kenudson,Tiffany Huynh,Carlotta Costa,Elizabeth L. Lockerman,Sarah F. Pollack,Manway Liu,Xiaoyan Li,Joseph Lehar,Marion Wiesmann,Markus Wartmann,Yan Chen,Z. Alexander Cao,Maria Pinzon-Ortiz,Sunkyu Kim,Robert Schlegel,Alan Huang,Jeffrey A. Engelman +19 more
TL;DR: The combination of PI3K and CDK 4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions in PIK3CA mutant xenografts.